Pfizer, Inc. (PFE) Insider Sells $1,338,050.00 in Stock
Pfizer, Inc. (NYSE:PFE) insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Pfizer, Inc. (NYSE PFE) traded up 1.06% during midday trading on Thursday, hitting $35.43. 2,648,893 shares of the stock were exchanged. The company has a market capitalization of $210.71 billion, a P/E ratio of 25.92 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.75. The company’s 50 day moving average is $33.44 and its 200 day moving average is $33.49.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share. Analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.65%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is 94.12%.
A number of research firms recently commented on PFE. BMO Capital Markets reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research note on Thursday. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research note on Wednesday. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, August 24th. Berenberg Bank reaffirmed a “hold” rating and issued a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Finally, Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and an average price target of $37.72.
Several hedge funds have recently bought and sold shares of PFE. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new position in shares of Pfizer in the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer in the second quarter worth approximately $103,000. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the last quarter. Finally, Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 612 shares during the last quarter. Institutional investors own 69.09% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.